These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 20010168)

  • 1. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for relapsed and refractory multiple myeloma.
    Lonial S; Mitsiades CS; Richardson PG
    Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of relapsed and relapsed refractory myeloma.
    Kastritis E; Mitsiades CS; Dimopoulos MA; Richardson PG
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1175-215, x. PubMed ID: 17996594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
    Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
    Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed and refractory myeloma.
    Kaufman J; Gleason C; Lonial S
    Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Greipp P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in treatment for relapses and refractory multiple myeloma.
    Richards T; Weber D
    Med Oncol; 2010 Jun; 27 Suppl 1():S25-42. PubMed ID: 20213220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
    Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
    Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating novel therapies in the transplant paradigm.
    Harousseau JL
    Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
    Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
    Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multiple myeloma -- therapy].
    Jung W; Zettl F; Schroers R
    Dtsch Med Wochenschr; 2005 Feb; 130(6):283-6; quiz 287-90. PubMed ID: 15692903
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel agents in myeloma: an exciting saga.
    Mark T; Niesvizky R; Coleman M
    Cancer; 2009 Jan; 115(2):236-42. PubMed ID: 19025986
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 38.